ERBB2 and breast cancer: A GP2-based vaccine (654-662, IISAVVGIL) has been tested in a phase IIb study + GM-CSF vs. GM-CSF alone after adjuvant trastuzumab in women with operable breast cancer and expressing any degree of HER2 (1-3+) [75].